“Incidence rate and time to serious adverse events among rifampicin resistant tuberculosis patients in Georgia treated with new and repurposed anti-tuberculosis drugs, 2016-2018 ” (2021) Monaldi Archives for Chest Disease, 91(1). doi:10.4081/monaldi.2021.1649.